摘要
目的观察晚期胃癌治疗中采用卡瑞利珠单抗联合白蛋白结合型紫杉醇二线治疗的效果。方法80例晚期胃癌患者,以随机数字表法分组为对照组和联合组,每组40例。对照组采用卡瑞利珠单抗注射治疗,联合组采用卡瑞利珠单抗联合白蛋白结合型紫杉醇二线治疗。对比两组患者临床疗效、治疗前后肿瘤标志物指标及不良反应发生率。结果经治疗联合组治疗总有效率95.00%高于对照组的77.50%,数据差异显著(P<0.05)。治疗后,联合组甲胎蛋白(26.45±5.52)μg/L、癌胚抗原(7.29±2.12)μg/L、前列腺特异抗原(6.20±1.28)μg/L、癌抗原19-9(38.46±7.12)U/ml低于对照组的(35.42±5.67)μg/L、(10.44±3.18)μg/L、(9.88±2.20)μg/L、(46.76±7.33)U/ml,数据差异显著(P<0.05)。治疗后联合组不良反应发生率25.00%高于对照组的20.00%,但无明显数据差异(P>0.05)。结论对晚期胃癌患者采用卡瑞利珠单抗联合白蛋白结合型紫杉醇二线治疗方案,可实现对患者肿瘤标志物水平的调节,有效改善临床症状,提升临床疗效,同时不良反应同单一用药方法相比相近,呈现出一定安全性,值得临床应用。
Objective To observe the effect of the combination of camrelizumab and albumin-bound paclitaxel in second-line treatment of advanced gastric cancer.Methods 80 patients with advanced gastric cancer were divided into a control group and a combination group using a random number table method,each consisting of 40 patients.The control group was treated with camrelizumab injection,while the combination group was treated with camrelizumab combined with albumin-bound paclitaxel second-line therapy.The clinical efficacy,and tumor markers before and after treatment,and the incidence of adverse reactions were compared between the two groups.Results After treatment,the total effective rate of the combination group was 95.00%,which was higher than 77.50%of the control group,and the difference was significant(P<0.05).After treatment,the combination group had alpha-fetoprotein of(26.45±5.52)μg/L,carcinoembryonic antigen of(7.29±2.12)μg/L,prostate-specific antigen of(38.46±7.12)μg/L,and carbohydrate antigen 19-9 of(6.20±1.28)U/ml,which were lower than(35.42±5.67)μg/L,(10.44±3.18)μg/L,(9.88±2.20)μg/L and(46.76±7.33)U/ml in the control group,and the difference was significant(P<0.05).After treatment,the incidence of adverse reactions in the combination group was 25.00%,which was higher than 20.00%in the control group,but there was no significant difference(P>0.05).Conclusion The combination of camrelizumab and albumin-bound paclitaxel second-line therapy for advanced gastric cancer patients can regulate tumor marker levels,effectively improve clinical symptoms,and enhance clinical efficacy.At the same time,the adverse reactions are similar to those of a single medication method,showing a certain degree of safety,and is worthy of clinical application.
作者
王品昊
WANG Pin-hao(Changzhou Hospital of Traditional Chinese Medicine,Changzhou 213161,China)
出处
《中国现代药物应用》
2024年第16期103-106,共4页
Chinese Journal of Modern Drug Application
